Advanced search
Publication Cover
Cancer Biology & Therapy Volume 16, 2015 - Issue 2
Submit an article Journal homepage
872
Views
4
CrossRef citations to date
0
Altmetric
Journal Clubs

Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma

Tracy C OkoliClinical Pharmacology Program; Center for Cancer Research; National Cancer Institute, Bethesda, MDUSA
,
Cody J PeerClinical Pharmacology Program; Center for Cancer Research; National Cancer Institute, Bethesda, MDUSA
,
Kieron DunleavyLymphoid Malignancies Branch; Center for Cancer Research; National Cancer Institute, Bethesda, MDUSA
&
William D FiggClinical Pharmacology Program; Center for Cancer Research; National Cancer Institute, Bethesda, MDUSACorrespondence[email protected]
Pages 204-206 | Received 12 Nov 2014, Accepted 18 Dec 2014, Published online: 10 Mar 2015

References

  • American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014.
  • DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Chapter 109. Lymphomas. In: Pharmacotherapy: A Pathophysiologic Approach, 9e. New York, NY: The McGraw-Hill Companies; 2014. Available at: http://mhmedical.com/content.aspx?aid=57513076.
  • Rituximab. In: Micromedex 2.0 [online database]. Greenwood Village: Thomson Reuters (Healthcare) Inc. Updated periodically. Accessed August 08, 2014.
  • Kocs D, Fendrick A. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care 2003; 9(5):393-400; quiz 401-402; PMID:12744301
  • Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370(11):1008-18; PMID:24450858; http://dx.doi.org/10.1056/NEJMoa1314583
  • Gilbert JA. Idelalisib: targeting PI3Kδ in B-cell malignancies. Lancet Oncol 2014; 15(3):e108; PMID:24809089; http://dx.doi.org/10.1016/S1470-2045(14)70052-X
  • Burns E, Vanhaesebroeck B. PIK3CD (phosphoinositide-3-kinase, catalytic, delta polypeptide). Atlas Genet Cytogenet Oncol Haematol 2012; 15(9):2009-12; http://dx.doi.org/10.4267/2042/46026
  • Cheson BD. CLL and NHL: the end of chemotherapy? Blood 2014; 123(22):3368-70; PMID:24876522; http://dx.doi.org/10.1182/blood-2014-04-563890
  • Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370(11):997-1007; PMID:24450857; http://dx.doi.org/10.1056/NEJMoa1315226
  • Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123(22):3390-7; PMID:24615777; http://dx.doi.org/10.1182/blood-2013-11-535047.The
  • Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014; 123(22):3406-13; PMID:24615776; http://dx.doi.org/10.1182/blood-2013-11-538546.There
  • Danilov A. Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther 2013; 35(9):1258-70; PMID:24054703; http://dx.doi.org/10.1016/j.clinthera.2013.08.004
  • Garber K. Kinase inhibitors overachieve in CLL. Nat Rev Drug Discov 2014; 13(3):162-4; PMID:24549135; http://dx.doi.org/10.1038/nrd4259

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.